Low Float (Nasdaq: MDCX) Sees Backing From 5 Potential Catalysts (Analyst Targets On Watch)

Biotech's pace is accelerating

*Disseminated on behalf of Medicus Pharma Ltd. Low Float (Nasdaq: MDCX) Sees Backing From 5 Potential Catalysts (Analyst Targets On Watch) October 24th Greetings, Friend! Biotech’s pace is accelerating, but few companies are tackling major health issues with bold innovation. One stands out for developing a dissolvable microneedle patch that delivers chemotherapy directly into tumors, aiming to revolutionize treatment for skin cancers such as basal cell carcinoma. The approach could offer patients a simpler, non-surgical alternative. Clinical trials are already progressing in the U.S. and UAE, and growth continues through the acquisition of a UK biotech advancing prostate therapies. These steps reflect a broader push toward safer, more effective disease treatments. Add in the fact that it has a float of fewer than 11Mn shares, a fresh acquisition just closed, and analyst targets suggesting meaningful upside potential—and it’s easy to see why this Nasdaq profile is catching attention. For perspective, after a recent alert, this profile jumped approximately 28%, climbing from an August 18th open of $2.10 to touch $2.69 in a few weeks. With a jump to over $3.00+ in September, it maxed out a move of roughly 45% while becoming a Nasdaq name to think about taking a closer look at. Take a moment to consider Medicus Pharma Ltd. (Nasdaq: MDCX) for your radar. Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents. Complete Company Details - Medicus Pharma Ltd. (Nasdaq: MDCX) Focus: Accelerating clinical development of novel therapeutics across multiple countries and continents. Specialty: Moving innovative therapies quickly through clinical stages. About SkinJect (Medicus Pharma's Wholly Owned Subsidiary) Product: Patented dissolvable microneedle patch (D-MNA) for non-melanoma skin cancer, especially basal cell carcinoma. Mechanism: Delivers doxorubicin directly to tumor via transdermal microneedles, aiming to replace invasive Mohs surgery with a painless, office-based treatment. Rights: Exclusive global development and commercialization rights from University of Pittsburgh and Carnegie Mellon since 2016. Clinical Progress Phase 1 (2021): Demonstrated safety, tolerability, and some complete responses. Phase 2: IND submitted to FDA in January 2024; patient recruitment began August 2024 at 9 US sites. Interim analysis (March 2025): Over 60% complete clinical response; trial expanded from 60 to 90 patients. SkinJect Value Proposition Innovation: Patented, non-invasive microneedle patch for direct drug delivery to skin tumors. Market: BCC is the most common cancer globally; North American market projected at $15Bn by 2030. Clinical Results: Positive safety and efficacy data in early trials, with ongoing Phase 2 showing promise. Leadership: Experienced management and board with oncology and drug development expertise. Medicus Pharma (Nasdaq: MDCX) is positioned to impact standards of care in both human and veterinary medicine, with ongoing clinical and regulatory milestones. ----- About Recent Acquisition: Antev Ltd. Antev Ltd. (“Antev”) is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, a potentially first in market product for high-risk prostate cancer patients and patients with first acute urinary retention (AUR) episodes due to enlarged prostate. Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. Teverelix: A Next-Gen GnRH Antagonist Teverelix is being developed to compete with or improve upon current GnRH antagonists like Degarelix and Relugolix as well as agonists. What sets Teverelix apart is the potential for: Rapid onset of testosterone suppression and prostate shrinkage Avoidance of testosterone flare versus agonists A longer-acting injection schedule (possibly every 6 weeks) Potential for subcutaneous and intra-muscular delivery without daily dosing (vs. Relugolix’s daily oral use) Due to superior formulation, ISRs potentially significantly milder compared to Degarelix What's Next for Teverelix? Find Sources Here: MDCX Presentation. MDCX Website. ----- 5 Potential Catalysts Could Provide (Nasdaq: MDCX) With A Breakout Spark! #1. A Low Float Scenario: With roughly 10.84Mn shares in its float, volatility potential could be heightened at the drop of a hat. #2. Two Analyst Targets Suggest MDCX May Be Undervalued. Take a look at this info found over at MarketBeat: From Thursday's close, the D. Boral Capital and Maxim Group targets project a potential upside of over 9,000% and 600%, respectively. More recently, Zacks Research provided MDCX with an "Upgrade" last month. From current chart levels, do these targets and upgrade signal (Nasdaq: MDCX) to be undervalued? #3. Groundbreaking Expansion Of Medicus Pharma’s Global Non-Invasive Cancer Treatment Trials. Medicus Pharma Ltd. has successfully treated the first patient in the UAE Phase 2 SKNJCT-004 trial, advancing its innovative non-invasive therapy for basal cell carcinoma (BCC). The 36-patient study, led by Cleveland Clinic Abu Dhabi and supported by five premier hospitals, underscores Medicus’s expanding international clinical footprint. Partnering with UAE-based IROS, the company enhances global research capabilities. This milestone follows positive U.S. trial results and an FDA-endorsed pathway for Skinject, reinforcing Medicus’s leadership in pioneering skin cancer treatments and global biotech innovation. #4. FDA Endorsement Boosts Medicus Pharma’s Innovative Non-Invasive Skin Cancer Therapy. Medicus Pharma Ltd. received encouraging FDA Type C meeting feedback supporting its Skinject D-MNA treatment for non-invasive basal cell carcinoma (BCC) therapy under the 505(b)(2) pathway. This regulatory alignment accelerates timelines, reduces development costs, and affirms Skinject’s ~$2Bn market potential. The FDA provided constructive guidance on study design, endpoints, and formulation optimization. With Phase 2 recruitment set to conclude in Q4 2025 and an EOP2 meeting planned in Q1 2026, Medicus strengthens its path toward anticipated commercialization by 2027. #5. Medicus Pharma Strengthens Pipeline With Strategic Acquisition Expanding Global Cancer Focus. Medicus Pharma Ltd. has successfully completed the acquisition of Antev Limited, a UK-based biotech developing Teverelix, a next-generation GnRH antagonist targeting acute urinary retention (AURr) and high cardiovascular risk prostate cancer. This first-in-class product addresses a market potential of approximately $6Bn. As part of the deal, veteran pharma executive Patrick J. Mahaffy, former CEO of Clovis Oncology and Pharmion, joins Medicus’s Board of Directors. The acquisition enhances Medicus’s innovative therapeutic pipeline, expands leadership expertise, and reinforces its commitment to delivering market-disruptive treatments for serious unmet medical needs. ----- Medicus Pharma Ltd. (Nasdaq: MDCX) sees coverage reinitiated from MPT. Updates will be coming shortly. Keep your eyes peeled.  All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 10/23/2025 and ending on 10/24/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid thirty seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/mdcx-oqnwc/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice